There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a…
At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.
In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock…
When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in…
“As an investor, this sets up a great opportunity to get in on the ground floor and earn triple-digit profits in short order,” advises the author of today’s article in regards to a little-known segment of the thriving biotech industry that appears poised for a massive breakout to the upside in the coming months. Just what is this biotech segment…
Given the fact that it has already demonstrated remarkable performance without even having any products with regulatory approval for sale, just where could biotech CRISPR Therapeutics, with its focus on the treatment of serious diseases using its proprietary CRISPR/Cas9 gene-editing platform, be five years from now? For more on the promise of this firm’s pipeline projects, CLICK HERE.
The man who has been ranked as the most accurate forecaster of US economic data eight years in a row by Bloomberg has some sobering warnings when it comes to the country’s recovery from the coronavirus pandemic – and how that could impact the current stock market rally. For what he has to say about how long it will take…
In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more…
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only…
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.